{"SPADE_N_14872": {"Sequence Information": {"Peptide Name": "Pseudofactin II, PFII", "Sequence": "GSTLLSLL", "Sequence Length": 8, "Biological Activity": ["Anti-Gram+", "Anti-Gram-", "Anticancer", "Antifungal", "Anti-Mammalian Cell"], "Binding Target": "1. Lipid Bilayer", "Source": "1. Pseudomonas fluorescens BD5", "Gene": "", "PDB ID": "", "UniProt Entry": [], "Literature": [{"Title": "Lipopeptide biosurfactant pseudofactin II induced apoptosis of melanoma A 375 cells by specific interaction with the plasma membrane.", "Pubmed ID": "23483962", "Reference": "PLoS One. 2013;8:e57991", "Author": "Janek T, Krasowska A, Radwańska A, Łukaszewicz M", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/23483962"}, {"Title": "Antiadhesive activity of the biosurfactant pseudofactin II secreted by the Arctic bacterium Pseudomonas fluorescens BD5.", "Pubmed ID": "22360895", "Reference": "BMC Microbiol. 2012;12:24", "Author": "Janek T, Łukaszewicz M, Krasowska A", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/22360895"}, {"Title": "Structure and mode of action of cyclic lipopeptide pseudofactin II with divalent metal ions.", "Pubmed ID": "27416562", "Reference": "Colloids Surf B Biointerfaces. 2016;146:498-506", "Author": "Janek T, Rodrigues LR, Gudiña EJ, Czyżnikowska Ż", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/27416562"}], "Mass": 802.96, "PI": 5.53, "Net Charge": 0, "Hydrophobicity": 1.56, "Frequent Amino Acids": "LSG", "Absent Amino Acids": "ACDEFHIKMNOPQRUVWY", "Basic Residues": 0, "Acidic Residues": 0, "Hydrophobic Residues": 4, "Polar Residues": 4, "Positive Residues": 0, "Negative Residues": 0, "SPADE ID": "SPADE_N_14872", "Similar Sequences": [{"SPADE_ID": "SPADE_N_02937", "Similarity": 1.0, "Sequence": "DLKHLILKAQLARCYKFGGFCYNSMCPPHTKFIGNCHPDHLHCCINMKELEGST"}, {"SPADE_ID": "SPADE_N_07459", "Similarity": 1.0, "Sequence": "GLLSGTSVRGST"}, {"SPADE_ID": "SPADE_UN_07048", "Similarity": 1.0, "Sequence": "MAEIVKFIYVMIIFLYLFLVSTNIEARQGCKIDYDCIKVVCKDGHAARCIMRRCECVEILNPIDLGST"}], "Hemolytic Activity": "Human dermal fibroblasts:50% Cell death=260 µM,Human Primary Epidermal Keratinocytes (HEK):50% Cell death=260 µM", "Target Organism": "Human melanoma A375(50% Cell death=65µM),Human melanoma A375(90-100% Killing=180µM),Staphylococcus epidermidis KCTC 1917(MIC=500µg/ml),Staphylococcus epidermidis KCTC 1917(MIC50=250µg/ml),Escherichia coli ATCC 25922(0-10% Inhibition=500µg/ml),Escherichia coli ATCC 10536(30-40% Inhibition=500µg/ml),Enterococcus faecalis ATCC 29212(10-20% Inhibition=500µg/ml),Enterococcus hirae ATCC 10541(20-30% Inhibition=500µg/ml),Proteus mirabilis ATCC 21100(30-40% Inhibition=500µg/ml),Candida albicans ATCC 10231(10-20% Inhibition=500µg/ml),Candida albicans SC5314(0-10% Inhibition=500µg/ml),Staphylococcus epidermidis KCTC 1917(10-20% Inhibition=72µM),Staphylococcus epidermidis KCTC 1917(20-30% Inhibition=72µM),Staphylococcus epidermidis KCTC 1917(40-50% Inhibition=72µM),Staphylococcus epidermidis KCTC 1917(50-60% Inhibition=72µM),Staphylococcus epidermidis KCTC 1917(60-70% Inhibition=72µM),Staphylococcus epidermidis KCTC 1917(50-60% Inhibition=240µM),Staphylococcus epidermidis KCTC 1917(50-60% Inhibition=240µM),Staphylococcus epidermidis KCTC 1917(70-80% Inhibition=240µM),Staphylococcus epidermidis KCTC 1917(90-100% Inhibition=240µM),Staphylococcus epidermidis KCTC 1917(90-100% Inhibition=240µM),Proteus mirabilis ATCC 21100(10-20% Inhibition=72µM),Proteus mirabilis ATCC 21100(10-20% Inhibition=72µM),Proteus mirabilis ATCC 21100(20-30% Inhibition=72µM),Proteus mirabilis ATCC 21100(40-50% Inhibition=72µM),Proteus mirabilis ATCC 21100(60-70% Inhibition=72µM),Proteus mirabilis ATCC 21100(30-40% Inhibition=240µM),Proteus mirabilis ATCC 21100(30-40% Inhibition=240µM),Proteus mirabilis ATCC 21100(50-60% Inhibition=240µM),Proteus mirabilis ATCC 21100(70-80% Inhibition=240µM),Proteus mirabilis ATCC 21100(90-100% Inhibition=240µM)"}}}